HDAC6 and pulmonary arterial hypertension: Inhibition of HDAC6 activity in PAH-PASMCs was first achieved using Tubastatin A (TubA) and ACY-775, two pharmacological inhibitors of HDAC631, 32 as well as by small interfering RNA.